A George Church spin­out fight­ing the vi­ral vec­tor bot­tle­neck in cell and gene ther­a­py lands $55M

A syn­thet­ic bi­ol­o­gy com­pa­ny spun out of George Church’s lab is set to tack­le the gene ther­a­py man­u­fac­tur­ing bot­tle­neck, and it just land­ed $55 mil­lion in a Se­ries A fi­nanc­ing round to do so.

64x Bio comes out of the Har­vard De­part­ment of Ge­net­ics. CEO Lex Rovn­er and her team — which right now, sits around 10 peo­ple — are look­ing to tack­le a key hur­dle for ma­jor com­pa­nies: man­u­fac­tur­ing cell and gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER